ArticleBritish journal of cancer1999
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
Article in British journal of cancer, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 204 citations in OpenAlex.
- Trial
- Lung endothelial PEAR1 induces tumor cell dormancy.Molecular cancer · 2025Article
- Cathepsin D Inhibits Angiogenesis in Pituitary Neuroendocrine Tumors.Acta histochemica et cytochemica · 2022Article
- Autophagy-related prognostic signature for survival prediction of triple negative breast cancer.PeerJ · 2022Article
- A review of gliomas-related proteins. Characteristics of potential biomarkers.American journal of cancer research · 2021Review
- A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.Theranostics · 2021Article
- Endosomes, lysosomes, and the role of endosomal and lysosomal biogenesis in cancer development.Molecular biology reports · 2020Review
- Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling.Nature communications · 2020Article
- Article
- Antiproliferative and Antimetastatic Effects of Praeruptorin C on Human Non-Small Cell Lung Cancer Through Inactivating ERK/CTSD Signalling Pathways.Molecules (Basel, Switzerland) · 2020Article
- Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer.JNCI cancer spectrum · 2020Article
- A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling.Frontiers in immunology · 2020Review
- Differences in cysteine peptidases-like activity in sera of patients with breast cancer.Cancer biomarkers : section A of Disease markers · 2020Article
- Prognostic role of high cathepsin D expression in breast cancer: a systematic review and meta-analysis.Therapeutic advances in medical oncology · 2020Article
- Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.Journal for immunotherapy of cancer · 2019Article
- Therapeutic Targeting of Cancer Stem Cells via Modulation of the Renin-Angiotensin System.Frontiers in oncology · 2019Review
- Grassystatins D-F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer.Journal of natural products · 2017Article
- Hispolon suppresses metastasis via autophagic degradation of cathepsin S in cervical cancer cells.Cell death & disease · 2017Article
- SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1.PLoS genetics · 2017Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is controversy regarding the prognostic value of cathepsin-D in primary breast cancer. An increased level of cathepsin-D in tumour extracts has been found to be associated with a poor relapse-free and overall survival. Studies performed with immunohistochemistry or Western blotting have produced diverse results. We have analysed 2810 cytosolic extracts obtained from human primary breast tumours for cathepsin-D expression, and have correlated their levels with prognosis. The median follow-up of the patients still alive was 88 months. Patients with high cathepsin-D levels had a significantly worse relapse-free and overall survival, also in multivariate analysis (P < 0.0001). Adjuvant therapy which was associated with an improved prognosis in node-positive patients in univariate analysis, also significantly added to the multivariate models for relapse-free and overall survival. There were no statistically significant interactions between the levels of cathepsin-D and any of the classical prognostic factors in analysis for relapse-free survival, suggesting that the prognostic value of cathepsin-D is not different in the various subgroups of patients. Indeed, multivariate analyses in subgroups of node-negative and -positive patients, pre- and post-menopausal patients, and their combinations, showed that tumours with high cathepsin-D values had a significantly poor relapse-free survival, with relative hazard rates ranging from 1.3 to 1.5, compared with tumours with low cathepsin-D levels. The results presented here on 2810 patients confirm that high cytosolic cathepsin-D values are associated with poor prognosis in human primary breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.